# US 2016/0251276 A1 · Agonist/antagonist compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251276 A1
- Document ID: US20160251276A1
- Status: Published application
- Kind: A1
- Application number: 15/010,830
- Filed: 2016-01-29
- Published: 2016-09-01
- Earliest claimed: 2010-03-12
- Applicants: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
- Inventors: Peter M. Blumberg; Larry V. Pearce
- Web page: https://patentgrep.com/patent/US20160251276A1

## CPC

- C06D 7/00: Compositions for gas-attacks
- A01N 37/18: containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A01N 43/46: rings with more than six members
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- F41H 9/10: Hand-held or body-worn self-defence devices using repellant gases or chemicals
- C06D: MEANS FOR GENERATING SMOKE OR MIST; GAS-ATTACK COMPOSITIONS; GENERATION OF GAS FOR BLASTING OR PROPULSION (CHEMICAL PART) (fuels C10)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- F41H: ARMOUR; ARMOURED TURRETS; ARMOURED OR ARMED VEHICLES; MEANS OF ATTACK OR DEFENCE, e.g. CAMOUFLAGE, IN GENERAL

## Abstract

The present invention relates to novel compositions comprising an agonist and an antagonist, in certain ratios which allow for the onset of agonist action followed quickly by alleviation by antagonist action, and methods of use in personal defense and law enforcement.

## Claims

### Claim 1

A composition comprising an effective amount of an agonist and an effective amount of an antagonist,
wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and
the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the agonist is a TRPV1 agonist and the antagonist is a TRPV1 antagonist,
wherein the TRPV1 agonist has a rate of penetration that is faster than the TRPV1 antagonist.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the TRPV1 agonist is antagonized by 80% by the TRPV1 antagonist, in about 1 minute to about 20 minutes.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the TRPV1 agonist is antagonized by 80% by the TRPV1 antagonist, in about 1 minute to about 5 minutes.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the TRPV1 agonist is capsaicin, dibenzoxazepine (CR), oleoresin capscium (OC), oleoresin paprika, paprika, capsicums (chili peppers), trans-8-methyl-N-vanillyl-6-nonenamide (capsaicin), 8-methyl-N-vanillyl-nonamide (dihydrocapsaicin), 7-methyl-N-vanillyl-octamide (nordihydrocapsaicin), 9-methyl-N-vanillyl-decamide (homodihydrocapsaicin), trams-9-methyl-N-vanillyl-7-decenamide (homocapsaicin), (3R,3,5R)-3,3′-dihydroxy-a,k-caroten-6′-one (capsanthin), N-vanillyl-octamide, N-vanillyl-nonamide, N-vanillyl-decanamide, N-vanillyl-undecanamide, N-vanillyl-paaiperic acid amide, nonivamide, civamide, olvanil, Nb-VNA, Nv-VNA, SB-705498, or anadamide.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the TRPV1 agonist is capsaicin.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the TRPV1 antagonist is BCTC, IodoRTX, JYL-827, AMG9810, capsazepine, SB-705498, Aprepitant, Lanpepitant, CP-99,994, SDZ NKT 343, Ezlopitant, CP-96345, CP-99994, CP-122721, MK-869, GR 205171. RP 67580, Dapitant, Lanepitant, Noloitanium, Sarefutant, Casopitant, or Vestipitant.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the TRPV1 antagonist is BCTC, IodoRTX, JYL-827, AMG9810, or capsazepine.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the agonist is an opiate agonist and the antagonist is an opiate antagonist.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the opiate agonist is fentanyl.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the opiate antagonist is diphenyl-6beta-naltrexamate or 6-beta-tosylnaltrexamate.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the agonist and antagonist are in a ratio of about 1:1 to about 10:1.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the agonist and antagonist are in a ratio of about 1:1 to about 1:10.

### Claim 14 (depends on 1)

The composition of claim 1, further comprising an additional therapeutic agent.

### Claim 15 (depends on 1)

The composition of claim 1, further comprising a surfactant, solubilizer, or emulsifier.

### Claim 16 (depends on 1)

A biocontrol agent comprising the composition of claim 1.

### Claim 17

A method for incapacitating a subject, comprising:
(a) providing a non-lethal temporarily incapacitating composition suitable for use in an aerosol or spray application, the incapacitating formulation comprising,
an effective amount of a TRPV1 agonist, an effective amount of a TRPV1 antagonist, and a solvent system; and
(b) applying the non-lethal temporarily incapacitating formulation to the subject;
wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.

### Claim 18 (depends on 17)

The method of claim 17, wherein the non-lethal temporarily incapacitating composition further comprises a propellant.

### Claim 19 (depends on 18)

The method of claim 18 wherein said propellant is miscible in said solvent system.

### Claim 20 (depends on 19)

The method of claim 19 wherein said propellant is carbon dioxide.

### Claim 21 (depends on 17)

The method of claim 17, wherein the TRPV1 agonist is antagonized by 80% by the TRPV1 antagonist, in about 1 minute to about 20 minutes.

### Claim 22 (depends on 21)

The method of claim 21, wherein the TRPV1 agonist is antagonized by 80% by the TRPV1 antagonist, in about 1 minute to about 5 minutes.

### Claim 23 (depends on 17)

The method of claim 17, wherein the TRPV1 agonist is capsaicin, dibenzoxazepine (CR), oleoresin capscium (OC), oleoresin paprika, paprika, capsicums (chili peppers), trans-8-methyl-N-vanillyl-6-nonenamide (capsaicin), 8-methyl-N-vanillyl-nonamide (dihydrocapsaicin), 7-methyl-N-vanillyl-octamide (nordihydrocapsaicin), 9-methyl-N-vanillyl-decamide (homodihydrocapsaicin), trans-9-methyl-N-vanillyl-7-decenamide (homocapsaicin), (3R,3,5R)-3,3′-dihydroxy-a,k-caroten-6′-one (capsanthin), N-vanillyl-octamide, N-vanillyl-nonamide, N-vanillyl-decanamide, N-vanillyl-undecanamide, N-vanillyl-paaiperic acid amide, nonivamide, civamide, olvanil, Nb-VNA, Nv-VNA, SB-705498, or anadamide.

### Claim 24 (depends on 23)

The method of claim 23, wherein the TRPV1 agonist is capsaicin

### Claim 25 (depends on 17)

The method of claim 17, wherein the TRPV1 antagonist is BCTC, IodoRTX, JYL-827, AMG9810, or capsazepine, SB-705498, Aprepitant, Lanpepitant, CP-99,994, SDZ NKT 343, Ezlopitant, CP-96345, CP-99994, CP-122721, MK-869, GR 205171. RP 67580, Dapitant, Lanepitant, Noloitanium, Sarefutant, Casopitant, or Vestipitant.

### Claim 26 (depends on 25)

The method of claim 25, wherein the TRPV1 antagonist is BCTC, IodoRTX, JYL-827, AMG9810, or capsazepine.

### Claim 27 (depends on 17)

The method of claim 17 wherein the TRPV1 agonist and antagonist are present in an amount of about 0.01% to about 5% by weight of the solvent system.

### Claim 28 (depends on 27)

The method of claim 27 wherein the TRPV1 agonist and antagonist are present in an amount of 0.1% to about 3% by weight of the solvent system.

### Claim 29 (depends on 17)

The method of claim 17 wherein the solvent system comprises approximately equal amounts of the propylene glycol dicaprylate/caprate and glycerol tris(2-ethylhexanoate).

### Claim 30 (depends on 17)

The method of claim 17 wherein said applying comprises spraying the non-lethal temporarily incapacitating formulation into the eyes of the subject.

### Claim 31 (depends on 17)

The method of claim 17 wherein said incapacitating composition is formulated to cause, upon application of the system to the facial area of a recipient, inflammation to the facial area of the recipient.

### Claim 32 (depends on 17)

The method of claim 17, wherein said application of the composition into the facial area of the subject causes the subject to experience a symptom selected from the group consisting of immediate closing of the eyes, shortness of breadth, and burning sensation.

### Claim 33 (depends on 32)

The method of claim 32, wherein the symptom lasts about 1 minute to about 45 minutes.

### Claim 34

A method for subduing a subject, comprising:
(a) providing a non-lethal temporarily incapacitating composition suitable for use in an aerosol or spray application, the incapacitating formulation comprising,
an effective amount of an opiate agonist, an effective amount of an opiate antagonist, and a solvent system; and
(b) applying the non-lethal temporarily incapacitating formulation to the subject;
wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.

### Claim 35

A pharmaceutical composition in the form of a solid carrier comprising: (a) an agonist, (b) an antagonist, (c) an effective solubilizing amount of at least one hydrophiliac surfactant, which is effective to partially or fully solubilize the agonist and antagonist in the solid carrier, and optionally (d) an additive;
wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the hydrophilic surfactant selected from the group consisting of (i) polyoxyethylene sorbitan fatty acid esters, (ii) polyoxyethylene-polyoxypropylene block copolymers, (iii) polyglycerol fatty acid esters, (iv) polyoxyethylene glycerides, (v) polyoxyethylene sterols, deriviatives, and analogues thereof, (vi) polyoxyehtylene vegetable oils, (vii) polyoxyethylene hydrogenated vegetable oils, (viii) reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols (ix) tocopheryl polyethylene glycol succinates, (x) sugar esters, (xi) sugar ethers, (xii) sucroglycerides, and (xiii) mixtures thereof; and (c) an additive to provide for controlled release of the active ingredient following administration to a patient, said additive selected from the group consisting of polyvinylpyrrolidone, polyethylene glycol, hydroxypropyl methylcellulose, hyrosypropyl cellulose and other cellulose derivatives and mixtures thereof.

### Claim 37 (depends on 35)

The composition of claim 35, wherein the additive is selected from the group consisting of solubilizers, enzyme inhibitors, anti-adherents, anticoagulants, antifoaming agents, antioxidants, binders, bufferants, chelating agents, coagulants, colorants, opaquants, coolants, cryoprotectants, diluents, fillers, disintegrants, super disintegrants, hydrogen bonding agents, flavorants, desensitizers, ion-exchange resins, plasticizers, preservatives, solvents, sweeteners, thickeners, and mixtures thereof.
